These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

919 related items for PubMed ID: 31862486

  • 1. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, Poynard T, Ratziu V, LIDO (Liver Injury in Diabetes and Obesity) Study Group.
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [Abstract] [Full Text] [Related]

  • 2. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A, Shasthry SM, Agarwal A, Bihari C, Jain P, Jindal A, Sarin S.
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [Abstract] [Full Text] [Related]

  • 3. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y, Kanı HT, Demirtaş CÖ, Kaya E, Sapmaz AF, Qutranji L, Alkayyali T, Batun KD, Batman M, Toy B, Çiftaslan A.
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [Abstract] [Full Text] [Related]

  • 4. Association between triglyceride glucose-body mass index and the staging of non-alcoholic steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.
    Zhang F, Han Y, Wu Y, Bao Z, Zheng G, Liu J, Li W.
    Ann Med; 2024 Dec; 56(1):2409342. PubMed ID: 39348274
    [Abstract] [Full Text] [Related]

  • 5. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.
    Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V, LIDO Study Group.
    J Hepatol; 2013 Sep; 59(3):550-6. PubMed ID: 23665288
    [Abstract] [Full Text] [Related]

  • 6. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease.
    Bedossa P, FLIP Pathology Consortium.
    Hepatology; 2014 Aug; 60(2):565-75. PubMed ID: 24753132
    [Abstract] [Full Text] [Related]

  • 7. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
    Huang Y, Gan Q, Lai R, Wang W, Guo S, Sheng Z, Chen L, Guo Q, Cai W, Wang H, Zhao G, Cao Z, Xie Q.
    Front Cell Infect Microbiol; 2021 Aug; 11():733348. PubMed ID: 35111690
    [Abstract] [Full Text] [Related]

  • 8. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H, Zhu X, Xia M, Yan H, Chang X, Hu X, Pan B, Guo W, Li X, Gao X.
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [Abstract] [Full Text] [Related]

  • 9. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, Lee KL, Kim W.
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [Abstract] [Full Text] [Related]

  • 10. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
    Nascimbeni F, Ballestri S, Machado MV, Mantovani A, Cortez-Pinto H, Targher G, Lonardo A.
    Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
    Sanyal AJ, Williams SA, Lavine JE, Neuschwander-Tetri BA, Alexander L, Ostroff R, Biegel H, Kowdley KV, Chalasani N, Dasarathy S, Diehl AM, Loomba R, Hameed B, Behling C, Kleiner DE, Karpen SJ, Williams J, Jia Y, Yates KP, Tonascia J.
    J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems.
    Leung HH, Puspanathan P, Chan AW, Nik Mustapha NR, Wong VW, Chan WK.
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1131-1138. PubMed ID: 35362158
    [Abstract] [Full Text] [Related]

  • 16. Transaminase Concentrations Cannot Separate Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Irrespective of Histological Algorithm.
    Lemmer P, Selbach N, Baars T, Porsch-Özcürümez M, Heider D, Canbay A, Sowa JP.
    Dig Dis; 2022 Jun; 40(5):644-653. PubMed ID: 34469884
    [Abstract] [Full Text] [Related]

  • 17. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C, Baselli G, Dongiovanni P, Fracanzani AL, Badiali S, Maggioni M, Craxi A, Fargion S, Prati D, Nobili V, Bugianesi E, Romeo S, Pihlajamaki J, Petta S, Valenti L.
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
    Johnson K, Leary PJ, Govaere O, Barter MJ, Charlton SH, Cockell SJ, Tiniakos D, Zatorska M, Bedossa P, Brosnan MJ, Cobbold JF, Ekstedt M, Aithal GP, Clément K, Schattenberg JM, Boursier J, Ratziu V, Bugianesi E, Anstee QM, Daly AK, LITMUS Consortium Investigators§, LITMUS Consortium Investigators.
    JHEP Rep; 2022 Feb; 4(2):100409. PubMed ID: 35072021
    [Abstract] [Full Text] [Related]

  • 20. Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis.
    Wang Q, You H, Ou X, Zhao X, Sun Y, Wang M, Wang P, Wang Y, Duan W, Wang X, Wu S, Kong Y, Saxena R, Gouw ASH, Jia J.
    Hepatol Int; 2019 Nov; 13(6):766-776. PubMed ID: 31559605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.